A Phase 2 interventional study of Enzalutamide Dose Escalation and Standard of Care in Prostate Cancer Patients, Elderly Patients and Pharmacokinetic Study, sponsored by Sunnybrook Health Sciences Centre. Not yet recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Sunnybrook Health Sciences Centre · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Prostatic Neoplasms by Sunnybrook Health Sciences Centre — 8 open to participants now, 15 under way, 1 of them phase 3. Prostatic Neoplasms · Sunnybrook Health Sciences Centre.
Among the 39 studies in Prostatic Neoplasms by Sunnybrook Health Sciences Centre, this one is the 27th largest by planned enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 2, reaches primary completion later than 6 of the 14 other live ones, and was the 37th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →8 of the 39 studies in Prostatic Neoplasms by Sunnybrook Health Sciences Centre are open now, in 1 country. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+ · Men only
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+ · Men only
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+ · Men only
Sunnybrook Health Sciences Centre · Sites in Canada
Men only
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 10 · Phase 3 1 · Phase 4 1
First in 2006; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 26 is below the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 30 across the 36 interventional studies, 100 across the 3 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sunnybrook Health Sciences Centre is the lead sponsor of 585 studies on the registry; 135 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
3 of the studies in Prostatic Neoplasms by Sunnybrook Health Sciences Centre that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06177093Sunnybrook Health Sciences CentrePilot Study of Dose Escalation in Prostate Radiotherapy Using the MR-Linac (DESTINATION-MRL) | 2026-12-01 |
| NCT07512076Sunnybrook Health Sciences CentreA Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer | 2027-07 |
| NCT02560181Sunnybrook Health Sciences CentrePilot Study of Whole Gland Salvage HDR Prostate Brachytherapy for Locally Recurrent Prostate Cancer | 2027-08-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies in Prostatic Neoplasms by Sunnybrook Health Sciences Centre, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase II, single-centre, pragmatic, non-randomized, dose escalation study to evaluate optimal dose levels of enzalutamide in elderly patients using pharmacokinetic blood sampling concentrations.
Enzalutamide is an androgen receptor pathway inhibitor (ARPI) drug that is commonly used in prostate cancer. It is safe, effective, and is generally well tolerated by patients at the standard dose of 160mg, however researchers have seen that it may cause unfavorable side effects in elderly patients 75 and older such as fatigue and cognitive impairment that impact their quality of life more significantly than those under 75.
To date there is limited research comparing differences in side effects and quality of life experienced by elderly patients on standard versus a lower dose of enzalutamide. Dose reductions are common, particularly in elderly patients, although they are not explicitly recommended on the drug label, and as a result this study seeks to build on the existing research and practice experience to evaluate how enzalutamide is metabolized in elderly patients and whether this difference warrants different dosing standards in these patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Main Cohort:
Advanced prostate cancer with a Health Canada approved indication for enzalutamide amongst the following:
Participant is capable, in the opinion of the investigator, of completing all study assessments and procedures, including blood draws for PK sampling according to the required schedule as per the study protocol as well as PROs.
Control Cohort:
Exclusion Criteria:
Main Cohort:
Control Cohort:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants 75 years and older who have have a confirmed diagnosis of advanced prostate cancer, and are suitable candidates to receive enzalutamide but have not started treatment with the drug yet.
Drug: Enzalutamide Dose Escalation
The control cohort will enroll participants that are under 70 years old, and are currently receiving enzalutamide for a period of more than 29 days.
Drug: Standard of Care
Participants will be allocated to receive one of 4 dose levels of enzalutamide; * Level 1: 40mg * Level 2: 80mg * Level 3: 120mg * Level 4: 160mg There will be 4 participants per dose level. After 8 weeks of treatment at the initial dose level, the study doctor will review treatment progress and may escalate to a higher dose level at their discretion. For each dose level participants move up to (if applicable), they will repeat this same 8 weeks of treatment and evaluation process.
Participants will continue to receive enzalutamide per standard of care.
Enzalutamide Plasma Levels
To compare enzalutamide plasma concentrations in patients ≥ 75 years of age with younger patients at various dose levels.
Time frame: At day 29 and 57 of all applicable dose levels, up to 32 weeks maximum (4 levels, 8 weeks apart)
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Jul 2027, 15 months later.
Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 15 months is below that.
Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sunnybrook Health Sciences Centre →